Mr. Anthony C. Hooper is the Executive Vice President - Global Commercial Operations of Amgen Inc. From March 2010 to October 2011, Mr. Hooper was Senior Vice President, Commercial Operations and President, U.S., Japan and …
The stock should run into initial resistance at its 50-day moving average (MA) of $152.63 and subsequent resistance at its 200-day MA of $154.90. SmarTrend is tracking the current trend status for Amgen Inc and will alert subscribers who …
AMGN closed May 9, 2018's trading session at $169.63. In the past year, the stock has hit a 52-week low of $152.16 and 52-week high of $201.23. Amgen stock has been showing support around $165.65 and resistance in the $172.53 range. …
It was a week that saw Edge Therapeutics crashing on news of discontinuation of its phase III study, Amgen’s Blincyto getting FDA’s nod for label expansion, EMA accepting Regeneron & Sanofi’s application for label expansion of …
Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market, with U.S. health regulators approving its version of the infection-fighting treatment.
Even though Amgen, Inc. (NASDAQ:AMGN) stock has one of the best-performing charts I’ve seen, it doesn’t get the respect it deserves. From a valuation perspective, it sells at a sizable discount to its competitors. Its price-earnings …